Fathimanoud, Correspondent, India Pharma Outlook
Sterile injectable CDMOs in India deliver end-to-end support across the product lifecycle. Their services typically cover:
These partners operate under WHO-GMP, ISO, and increasingly US FDA or EMA-aligned standards. They handle a wide range of products, including small molecules, large molecules, suspensions, monoclonal antibodies, and mRNA-based therapies.
Capability | What the CDMO provides |
Formulation development | Injectable formulation optimization |
Aseptic processing | Sterile manufacturing under controlled environments |
Fill-finish | Filling and closing of vials/ampoules/PFS |
Lyophilization | Freeze-drying of sensitive formulations |
Analytical testing | Release, stability and microbiological testing |
Technology transfer | Transfer from development to commercial scale |
Scale-up | Engineering and commercial batches |
Regulatory support | Documentation and market-specific requirements |
The Indian government has introduced targeted programs to strengthen domestic sterile injectable manufacturing and reduce external dependence. The Production Linked Incentive (PLI) Scheme, launched with an outlay of Rs 6,940 crore for 2022–23 to 2028–29, provides financial incentives based on incremental sales for manufacturers of bulk drugs and injectables.
A renewed application window in May 2025 covered 11 key APIs and intermediates, enabling capacity expansion and stronger reverse integration.
Complementary initiatives such as the Jan Aushadhi scheme improve access to affordable, quality-assured generic injectables, while the National Policy on Research and Development and Innovation in the Pharma-MedTech sector supports advances in complex injectables and drug-delivery systems.
Together, these measures help Indian sterile injectable CDMOs scale production, raise quality standards and compete more effectively in global markets.
Also Read: Why Global Pharma is Moving to India: The 2026 India CDMO Boom and Market Outlook
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")